FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897912680> ?p ?o ?g. }

• W2897912680 endingPage "96" @default.
• W2897912680 startingPage "88" @default.
• W2897912680 abstract "Purpose Histoplasmosis is a known complication of systemic immunosuppressive therapy, particularly among patients who are receiving tumor necrosis factor α inhibitors. There are limited data on the development of disseminated or pulmonary histoplasmosis among patients who are receiving systemic immunosuppressive medication for noninfectious ocular inflammation. Design Retrospective case series. Methods We reviewed all patients with uveitis or scleritis who subsequently developed pulmonary or disseminated histoplasmosis at the Mayo Clinic in Rochester, Minnesota between September 1, 1994 and July 1, 2017, with a 3:1 age- and sex-matched control cohort who did not develop histoplasmosis. This was a single institutional study examining patients that developed histoplasmosis after the initiation of systemic immunomodulatory therapy (IMT). Patients had to develop either disseminated or pulmonary histoplasmosis while receiving systemic immunosuppressive therapy and have an ophthalmic examination at Mayo Clinic Rochester. The control group was comprised of patients who received systemic IMT for ocular inflammation but did not develop histoplasmosis. Results Nine cases of histoplasmosis were identified: 2 disseminated and 7 pulmonary. Both patients with disseminated histoplasmosis were taking tumor necrosis factor α inhibitors. Seven of the 9 patients received systemic antifungal medication, including both disseminated cases. Over a median follow-up of 4.4 years, none of the patients died, and there were no recurrences of histoplasmosis. When compared to the control cohort, there was no correlation between length of time on IMT and the risk of histoplasmosis. Conclusions Ocular inflammation patients on systemic immunomodulatory therapy may develop pulmonary or disseminated histoplasmosis. Most cases require treatment with systemic antifungal medication, but it might not be necessary to stop systemic immunomodulatory medication for ocular inflammation. Ophthalmologists should be aware that patients receiving systemic immunomodulatory therapy have a higher risk of developing Histoplasma infections. Prompt diagnosis and treatment using the expertise of an infectious diseases specialist may ensure low mortality for these patients. Histoplasmosis is a known complication of systemic immunosuppressive therapy, particularly among patients who are receiving tumor necrosis factor α inhibitors. There are limited data on the development of disseminated or pulmonary histoplasmosis among patients who are receiving systemic immunosuppressive medication for noninfectious ocular inflammation. Retrospective case series. We reviewed all patients with uveitis or scleritis who subsequently developed pulmonary or disseminated histoplasmosis at the Mayo Clinic in Rochester, Minnesota between September 1, 1994 and July 1, 2017, with a 3:1 age- and sex-matched control cohort who did not develop histoplasmosis. This was a single institutional study examining patients that developed histoplasmosis after the initiation of systemic immunomodulatory therapy (IMT). Patients had to develop either disseminated or pulmonary histoplasmosis while receiving systemic immunosuppressive therapy and have an ophthalmic examination at Mayo Clinic Rochester. The control group was comprised of patients who received systemic IMT for ocular inflammation but did not develop histoplasmosis. Nine cases of histoplasmosis were identified: 2 disseminated and 7 pulmonary. Both patients with disseminated histoplasmosis were taking tumor necrosis factor α inhibitors. Seven of the 9 patients received systemic antifungal medication, including both disseminated cases. Over a median follow-up of 4.4 years, none of the patients died, and there were no recurrences of histoplasmosis. When compared to the control cohort, there was no correlation between length of time on IMT and the risk of histoplasmosis. Ocular inflammation patients on systemic immunomodulatory therapy may develop pulmonary or disseminated histoplasmosis. Most cases require treatment with systemic antifungal medication, but it might not be necessary to stop systemic immunomodulatory medication for ocular inflammation. Ophthalmologists should be aware that patients receiving systemic immunomodulatory therapy have a higher risk of developing Histoplasma infections. Prompt diagnosis and treatment using the expertise of an infectious diseases specialist may ensure low mortality for these patients." @default.
• W2897912680 created "2018-10-26" @default.
• W2897912680 creator A5051866792 @default.
• W2897912680 creator A5064919549 @default.
• W2897912680 date "2019-02-01" @default.
• W2897912680 modified "2023-09-26" @default.
• W2897912680 title "Histoplasmosis Following Systemic Immunomodulatory Therapy for Ocular Inflammation" @default.
• W2897912680 cites W1899841286 @default.
• W2897912680 cites W1965471924 @default.
• W2897912680 cites W1972526834 @default.
• W2897912680 cites W1977776126 @default.
• W2897912680 cites W1990430831 @default.
• W2897912680 cites W2028178787 @default.
• W2897912680 cites W2044324436 @default.
• W2897912680 cites W2049487760 @default.
• W2897912680 cites W2050846744 @default.
• W2897912680 cites W2076863034 @default.
• W2897912680 cites W2085942622 @default.
• W2897912680 cites W2111855467 @default.
• W2897912680 cites W2112861894 @default.
• W2897912680 cites W2114004413 @default.
• W2897912680 cites W2150499428 @default.
• W2897912680 cites W2340567530 @default.
• W2897912680 doi "https://doi.org/10.1016/j.ajo.2018.09.033" @default.
• W2897912680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30308204" @default.
• W2897912680 hasPublicationYear "2019" @default.
• W2897912680 type Work @default.
• W2897912680 sameAs 2897912680 @default.
• W2897912680 citedByCount "4" @default.
• W2897912680 countsByYear W28979126802018 @default.
• W2897912680 countsByYear W28979126802020 @default.
• W2897912680 countsByYear W28979126802021 @default.
• W2897912680 countsByYear W28979126802022 @default.
• W2897912680 crossrefType "journal-article" @default.
• W2897912680 hasAuthorship W2897912680A5051866792 @default.
• W2897912680 hasAuthorship W2897912680A5064919549 @default.
• W2897912680 hasConcept C126322002 @default.
• W2897912680 hasConcept C141071460 @default.
• W2897912680 hasConcept C16005928 @default.
• W2897912680 hasConcept C167135981 @default.
• W2897912680 hasConcept C2776252253 @default.
• W2897912680 hasConcept C2776914184 @default.
• W2897912680 hasConcept C2780318139 @default.
• W2897912680 hasConcept C71924100 @default.
• W2897912680 hasConceptScore W2897912680C126322002 @default.
• W2897912680 hasConceptScore W2897912680C141071460 @default.
• W2897912680 hasConceptScore W2897912680C16005928 @default.
• W2897912680 hasConceptScore W2897912680C167135981 @default.
• W2897912680 hasConceptScore W2897912680C2776252253 @default.
• W2897912680 hasConceptScore W2897912680C2776914184 @default.
• W2897912680 hasConceptScore W2897912680C2780318139 @default.
• W2897912680 hasConceptScore W2897912680C71924100 @default.
• W2897912680 hasFunder F4320306811 @default.
• W2897912680 hasLocation W28979126801 @default.
• W2897912680 hasLocation W28979126802 @default.
• W2897912680 hasOpenAccess W2897912680 @default.
• W2897912680 hasPrimaryLocation W28979126801 @default.
• W2897912680 hasRelatedWork W113810927 @default.
• W2897912680 hasRelatedWork W1586374228 @default.
• W2897912680 hasRelatedWork W2003938723 @default.
• W2897912680 hasRelatedWork W2047967234 @default.
• W2897912680 hasRelatedWork W2118496982 @default.
• W2897912680 hasRelatedWork W2364998975 @default.
• W2897912680 hasRelatedWork W2369162477 @default.
• W2897912680 hasRelatedWork W2439875401 @default.
• W2897912680 hasRelatedWork W4238867864 @default.
• W2897912680 hasRelatedWork W2525756941 @default.
• W2897912680 hasVolume "198" @default.
• W2897912680 isParatext "false" @default.
• W2897912680 isRetracted "false" @default.
• W2897912680 magId "2897912680" @default.
• W2897912680 workType "article" @default.